Combination therapy for treating cancer
AssigneeLeukos Biotech, S.L.
InventorsRuth Muñoz Risueño, Mari Carmen Lara Castillo, Amaia Etxabe Alberdi
Life of this patent
Estimating the term…
Abstract
The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
Claims16
A synergistic combination for the treatment of a hematological malignancy comprising
- (a) an antineoplastic agent selected from the group consisting of cytarabine, azacytidine, decitabine, cladribine, fludarabine and methotrexate;
- and
- (b) a type 1A or type 1B HTR serotonin receptor (HTR1A or HTR1B) small molecule antagonist, at a molar ratio of HTR1A or HTR1B small molecule antagonist to antineoplastic agent between
- (i) 40:1 and 2:1 when the antineoplastic agent is cytarabine;
- (ii) 100:1 and 2:1 when the antineoplastic agent is azacitidine;
- (iii) 500:1 and 50:1 when the antineoplastic agent is decitabine;
- (iv) 1000:1 and 100:1 when the antineoplastic agent is cladribine;
- (v) 50:1 and 5:1 when the antineoplastic agent is fludarabine;
- or
- (vi) 4000:1 to 400:1 when the antineoplastic agent is methotrexate
- wherein the synergistic combination comprising an antineoplastic agent and an HTR1A or HTR1B small molecule antagonist is capable of synergistically killing hematological malignancy cells expressing HTR1A or HTR1B.
Dependencies are inferred from the claim text.